Journal Article (Editorial)

DZNE-2026-00572

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC.

Frederiksen, K. S. ; Boada, M. ; Frölich, L. ; Kramberger, M. ; Scarmeas, N. ; Vijverberg, E. ; Visser, P. J. ; Waldemar, G. ; Westman, E. ; Zetterberg, H. ; Engelborghs, S. ; Jessen, F. (Last author)DZNE*

2026
Elsevier Masson SAS [Paris]

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/j.tjpad.2026.100598

Keyword(s): Alzheimer's disease ; Anti-amyloid ; Monocloncal antibodies

---

Contributing Institute(s):

1. Clinical Alzheimer’s Disease Research (AG Jessen)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

---

Database coverage:
; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Springer ; DEAL Springer ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---